Living donor liver transplantation can be a rescue treatment for hepatocellular carcinoma  

作　　者：Jongman Kim 

机构地区：[1]Department of Surgery,Samsung Medical Center,Sungkyunkwan University School of Medicine,Seoul,Republic of Korea

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第4期742-744,共3页肝胆外科与营养（英文）

基　　金：Basic Research Program through the National Research Foundation of Korea(NRF)funded by the Ministry of Science and ICT(No.NRF-2023R1A2C2005946).Korean NRF did not influence the drafting of the manuscript.

摘　　要：For intermediate-stage hepatocellular carcinoma(HCC)in the Barcelona Clinic Liver Cancer(BCLC),transarterial chemoembolization(TACE)is advised as the initial treatment.The term“BCLC intermediate-stage HCC”(BCLC stage B)refers to a group of patients with varying liver functions and single big nodules or many nodules that do not have distant metastases or vascular invasion(1).In general,tumors beyond the Milan criteria(single tumor>5 cm or≥4 nodules)are classified as BCLC intermediate-stage HCC.Consequently,not every patient with intermediate-stage HCC in BCLC is a good candidate for TACE alone;this is especially true for patients who have a substantial tumor bulk,multinodular dissemination,or decreased liver function.TACE refractory cases cannot get full TACE treatment.

关 键 词：Living liver donors outcomes guidelines Barcelona Clinic Liver Cancer staging(BCLC staging) 

分 类 号：R735.7[医药卫生—肿瘤]